The World Health Organisation (WHO) on Wednesday advised patients with mild or moderate cases of the Coronavirus (COVID-19) against the use of antidepressant drug, fluvoxamine, and the gout drug colchicine.
The organisation said in a statement that current indications did not justify using colchicine to treat non-severe illness, addding that fluvoxamine should not be used without clinical trials.
According to report by a WHO Guideline Development Group (GDG), the advice became necessary due to insufficient evidence of better results from the use of the drugs and their potential harm. panel of international experts in the British Medical Journal.
The report, put together by a panel of international experts in the British Medical Journal, said no recommendation was made for either drug in patients with severe or critical illness, given limited or no data.
Who said that “Fluvoxamine and colchicine are commonly used, inexpensive drugs that have received considerable interest as potential COVID-19 treatments during the pandemic.
It said that the WHO’s advice against the use of fluvoxamine except in clinical trials was informed by data from three randomised controlled trials (RCTs) involving over 2,000 patients.
It also said that the panel noted that none of the included studies enrolled children, so the applicability of these recommendations to children is uncertain.
WHO also warned against the use of convalescent plasma, ivermectin, and hydroxychloroquine in patients with COVID-19 regardless of disease severity.